Dr. Patrik Frei, as the founder and CEO of Venture Valuation AG, has established himself as a leading authority in the independent valuation of private equity companies, particularly within the dynamic sectors of biotech, medtech, and pharmaceuticals. With over 1,000 valuations conducted across the US,...
Dr. Patrik Frei, as the founder and CEO of Venture Valuation AG, has established himself as a leading authority in the independent valuation of private equity companies, particularly within the dynamic sectors of biotech, medtech, and pharmaceuticals. With over 1,000 valuations conducted across the US, Europe, and Asia, Patrik brings a wealth of expertise that is invaluable to investors and companies navigating complex financial landscapes. His firm specializes in providing comprehensive valuation services, including fairness opinions, which are crucial for stakeholders involved in mergers and acquisitions, reverse mergers, and licensing agreements.
Under Patrik's leadership, Venture Valuation has become a trusted partner for a diverse clientele, ranging from corporate investors and venture capitalists to family offices and business angels. The firm’s rigorous approach to product valuation not only aids in licensing negotiations but also serves as a benchmark for companies seeking to understand their market position and potential for commercialization. Patrik’s deep understanding of the pharmaceutical industry, coupled with his skills in strategy, technology transfer, and innovation management, allows him to deliver insights that drive strategic partnerships and facilitate successful financing deals.
In addition to his valuation work, Patrik is actively involved in thought leadership within the industry, contributing to the discourse on drug discovery and the commercialization of high-tech solutions. His published papers, available on the Venture Valuation website, provide a glimpse into his analytical approach and the methodologies employed in biotech valuations. Through his dedication to excellence and a keen understanding of market dynamics, Patrik Frei continues to shape the future of valuation services in the life sciences sector.
